Hims & Hers Health, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Hims & Hers Health, Inc. operates a telehealth platform providing direct-to-consumer healthcare services and products primarily across the United States, the United Kingdom, and select European markets, with plans for further global expansion. The company offers a comprehensive range of core products and services including prescription medications, over-the-counter drugs, and personal care products under its consumer-facing brands Hims (targeting men) and Hers (targeting women). Key product categories encompass sexual health treatments such as erectile dysfunction medications and birth control; hair care products including hair loss treatments; mental health services including therapy and coaching; weight loss programs integrating medication; skincare products; and preventive health solutions. The platform connects customers with licensed healthcare providers who deliver personalized treatment plans through virtual consultations, often asynchronously, supported by ongoing clinical care and educational resources. Hims & Hers also operates vertically integrated pharmacy fulfillment facilities alongside partnerships with external pharmacies for prescription delivery. Founded in 2017 and headquartered in San Francisco, California, Hims & Hers has rapidly evolved from focusing initially on men's health and stigmatized conditions like erectile dysfunction to a broad telehealth ecosystem covering multiple specialties and wellness areas for both men and women. Recent major developments include the acquisition of YourBio Health, which brings advanced pain-free blood sampling technology to enhance diagnostic services, and the strategic acquisition of ZAVA, a leading European digital health platform, which expands Hims & Hers’ footprint into the UK, Germany, France, and Ireland with plans to further penetrate European markets. The company also announced a significant collaboration with Novo Nordisk to expand affordable access to obesity care, alongside launching AI-powered tools like MedMatch to personalize treatment plans using large-scale data analytics. Additionally, Hims & Hers initiated a $250 million share repurchase program in 2025 and planned a market entry into Canada timed with availability of generic weight loss medication semaglutide. Hims & Hers operates within the broader healthcare and biotechnology sectors and targets adult consumers seeking accessible, affordable, and stigma-free telehealth services and products. Its business model integrates telemedicine consultations, electronic medical records, cloud-based pharmacy fulfillment, and personalized healthcare technology. With over 2.4 million subscribers as of mid-2025, the company has scaled its operations nation-wide in the US and strategically expanded internationally through acquisitions and partnerships with major health systems like Ochsner, Mount Sinai, and Hartford Healthcare to enhance continuity of care that bridges digital and in-person services. The firm's continuous innovation and targeted market expansion position it as a growing leader in global digital health and wellness delivery.
Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know
A Look at Hims & Hers Health Inc (HIMS) After 5.4% Decline -- GF Value $38.53 vs Price $33.54
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
Hims & Hers Stock Jumps After Barclays Raises Price Target
Living Longer Is Big Business. These Stocks Will Benefit.
Hims & Hers: The Bull Case Remains Strong
Hims & Hers Health, Inc. (HIMS) Ascends While Market Falls: Some Facts to Note
Hims & Hers Enters A New Phase
Hims & Hers Health Stock Slides Friday: What's Going On?
The GLP-1 stock nobody is pricing in isn't a drugmaker
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today
OMCL vs. HIMS: Which Stock Is the Better Value Option?
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue?
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.7% Rally? GF Value Says Undervalued
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims
Hims & Hers Expands With Eucalyptus Acquisition